Cipla Ltd · NSE:CIPLA
Cipla — Q3 FY2023 Earnings Presentation
19 slides from Cipla's earnings presentation, Jan 25, 2023
Slide 1: Investor Presentation Q3FY23
CLICK TO EDIT MASTER TITLE STYLE Investor Presentation Q3FY23 25-1-2023
Slide 2: Disclaimer
DISCLAIMER CLICK TO EDIT MASTER TITLE STYLE Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact o
Slide 3: Q3FY23 Performance: Key Highlights
Q3FY23 Performance CLICK Continued TOtraction strong EDIT inMASTER One-IndiaTITLE and USSTYLE differentiated portfolio drive revenue and profitability KEY HIGHLIGHTS Overall Revenue EBITDA Margin R&D Investment1 Continued investment INR 5,810 Cr INR 1,408 Cr 24.2% INR 363 Cr in respiratory, biosimil
Slide 4: Financial Performance – Q3FY23
Financial Performance – Q3FY23 CLICK TO EDIT MASTER TITLE STYLE Revenues INR 5,810 Cr EBITDA INR 1,408 Cr Revenue1 Break-up Q3 FY23 (Consolidated) Actuals API, 3% Others, 1% vs Q3 FY22 (INR Cr) International Total Revenue from Markets, 5,810 6% Operations 13% EBITDA 1,408 13% SAGA, EBITDA % of reven
Slide 5: Continued focus on building balance sheet strength
Continued focus on building balance sheet strength CLICK TO EDIT MASTER TITLE STYLE Total Debt1 Cash Balances2 Net Cash3 (INR Cr) (INR Cr) (INR Cr) 6,232 4,965 5,060 5,190 3,909 3,992 1,068 1,056 1,042 Mar'22 Sept'22 Dec'22 Mar'22 Sept'22 Dec'22 Mar'22 Sept'22 Dec'22 1. Total debt includes lease lia
Slide 6: One India: Strong execution across portfolio and distribution
One India (Rx + Gx+ CHL1): Strong execution across portfolio and CLICK TO distribution EDIT MASTER helping TITLE us drive STYLEacross the three businesses growth INR Cr INR Cr 7,644 7,609 2,518 2,563 Q3FY22 Q3FY23 YTD FY22 YTD FY23 Prescription Trade generics Consumer health Prescription Trade gener
Slide 7: Branded prescription business continues to deliver market beating growth
Our branded prescription business continues to deliver market CLICK beating TO EDIT growth MASTER driven by TITLE STYLE growing share of chronic therapies 7th consecutive quarter of market beating growth in core portfolio over previous year 17.9 42% 17.1 14.8 38% 12.8 29% 11.611.3 11.8 11.7 11.2 16%
Slide 8: Global consumer wellness franchise improving health outcomes
Global consumer wellness franchise improving health outcomes CLICK TO EDIT MASTER TITLE STYLE One-India Flagship Brands 975+ INR Cr ↑ 28% ↑ 23% ↑ 5% ↑ 11% 9MFY23 revenue 8.5% ↑ 36% ↑ 24% ↑ 7% ↑ 30% Contribution of Global South Africa Consumer franchise to overall revenues in Flagship Brands 9MFY23 (
Slide 9: North America: Continued momentum on expansion in share of differentiated products
North America: Continued momentum on the back of expansion in CLICK share TO EDIT MASTER of differentiated TITLE STYLE products 10th consecutive quarter of growth in revenue over previous year Leuprolide inj. 50% 245 North America Revenue ($m) YoY growth Lenalidomide Lanreotide inj. launch 45% launc
Slide 10: North America: Continued momentum on expansion in share of differentiated products
North America: Continued momentum on the back of expansion in CLICK share TO EDIT MASTER of differentiated TITLE STYLE products North America Highest ever quarterly revenue driven by steady contribution from Lenalidomide, market share expansion in respiratory & $ Mn peptide products, offsetting pric
Slide 11: ANDA & NDA Portfolio & Pipeline
ANDA & NDA Portfolio & Pipeline (As on 31st December 2022) CLICK TO EDIT MASTER TITLE STYLE 14 59 9 4 19 2 8 78 1 43 8 8 Approved Tentatively Under Approval ANDAs/NDAs Approved ANDAs ANDAs/NDAs 1 Cipla Ltd PEFPAR Invagen Partnered ANDAs/NDAs 160 19 74 253 Approved Tentatively Under Approval Total AN
Slide 12: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global Access CLICK TO EDIT MASTER TITLE STYLE $ Mn Q3 Y-o-Y South Africa2 8 36 ❖ Supply challenges being addressed; evolving business mix between private and tender 23 16 12 ❖ In secondary terms, strong demand continues with overall South Africa pri
Slide 13: International Markets and API
International Markets and API CLICK TO EDIT MASTER TITLE STYLE International Markets API Q3 Y-o-Y Q3 Y-o-Y INR Cr 738 762 INR Cr 150 147 $ Mn 98 93 $ Mn 20 18 Q3FY22 Q3FY23 Q3FY22 Q3FY23 Key Business Highlights Key Business Highlights ❖ $ revenue impacted by currency volatility; ❖ Continued growth i
Slide 14: New Partnerships for Innovation
New Partnerships for Innovation CLICK TO EDIT MASTER TITLE STYLE Partnering in development of mRNA-based therapies ❑ Ethris GmbH is global leader in delivering mRNAs directly to the respiratory system including administration by inhalation ❑ Cipla signed definitive agreements for equity investment o
Slide 15: ESG Update
ESG Update CLICK TO EDIT MASTER TITLE STYLE Continued Progress on ESG Goals • Healthy progress on renewable energy plan till date • Projects in water conservation • Captive Open Access Projects: initiated with multiple NGOs in 61 MWp completed field of Natural Resource Carbon • Onsite Roof-top/ Grou
Slide 16: Continued progress on our strategic priorities
Continued progress on our strategic priorities CLICK TO EDIT MASTER TITLE STYLE Accelerate growth Building big prescription brands across Driving penetration and Consumer insighting driving portfolio in One-India chronic therapies, improved accessibility of brands for unmet expansion to address well
Slide 17: Profit and Loss statement summary
Profit and Loss statement summary CLICK TO EDIT MASTER TITLE STYLE Q3 FY23 Q2 FY23 Q3 FY22 Particulars (INR Crores) (INR Crores) (INR Crores) Revenue from sale of products 5,730.1 5,759.3 5,442.9 Other operating income 80.0 69.3 36.0 Income from operations 5,810.1 5,828.5 5,478.9 Material cost 2,004
Slide 18: Balance sheet summary
Balance sheet summary CLICK TO EDIT MASTER TITLE STYLE Dec-22 Sep-22 Mar-22 Dec-22 Sep-22 Mar-22 Particulars Particulars (INR Crores) (INR Crores) (INR Crores) (INR Crores) (INR Crores) (INR Crores) Property, plant and equipment 5,077.6 5,080.0 5,164.4 Share capital 161.4 161.4 161.4 Capital work-in
Slide 19: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com Ankit Bhembre Investor.Relations@cipla.com For more information please visit www.cipla.com